Priapism, an emerging complication in β-thalassemia intermedia patients
| dc.contributor.author | Mallat, Naji S. | |
| dc.contributor.author | Wehbe, David | |
| dc.contributor.author | Haddad, Anthony G. | |
| dc.contributor.author | Cappellini, Maria Teresa | |
| dc.contributor.author | Marcon, Alessia | |
| dc.contributor.author | Koussa, Suzanne C. | |
| dc.contributor.author | Abboud, Miguel Raul | |
| dc.contributor.author | Radwan, Amr H. | |
| dc.contributor.author | Taher, Ali T. | |
| dc.contributor.department | Internal Medicine | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:43:01Z | |
| dc.date.available | 2025-01-24T11:43:01Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | The increase in survival rate of β-thalassemia (β-thal) patients allowed for the appearance and manifestation of several complications in almost every organ system. Priapism in β-thal patients is rarely reported in the literature. We herein report and investigate the occurrence of two cases of priapism in two young patients with β-thal intermedia (β-TI). The potential mechanisms are due to either a cellular mechanism involving a thrombus obstructing the efferent venules of the corpora cavernosa leading to priapism, or a recently elucidated functional mechanism that causes alteration of nitric oxide (NO) response of the penis, ultimately causing priapism. This should incite clinicians for a close follow-up and monitoring of high risk patients who are susceptible to developing priapism. © 2014 Informa Healthcare USA, Inc. All rights reserved. | |
| dc.identifier.doi | https://doi.org/10.3109/03630269.2014.960087 | |
| dc.identifier.eid | 2-s2.0-84907483028 | |
| dc.identifier.pmid | 25271993 | |
| dc.identifier.uri | http://hdl.handle.net/10938/30173 | |
| dc.language.iso | en | |
| dc.publisher | Informa Healthcare | |
| dc.relation.ispartof | Hemoglobin | |
| dc.source | Scopus | |
| dc.subject | Hypercoagulability | |
| dc.subject | Nitric oxide (no) | |
| dc.subject | Priapism | |
| dc.subject | Β-thalassemia intermedia (β-ti) | |
| dc.subject | Adrenergic beta-antagonists | |
| dc.subject | Adult | |
| dc.subject | Beta-thalassemia | |
| dc.subject | Combined modality therapy | |
| dc.subject | Drug combinations | |
| dc.subject | Histamine h1 antagonists | |
| dc.subject | Humans | |
| dc.subject | Male | |
| dc.subject | Propranolol | |
| dc.subject | Pseudoephedrine | |
| dc.subject | Severity of illness index | |
| dc.subject | Treatment outcome | |
| dc.subject | Triprolidine | |
| dc.subject | Beta adrenergic receptor blocking agent | |
| dc.subject | Drug combination | |
| dc.subject | Histamine h1 receptor antagonist | |
| dc.subject | Pseudoephedrine, triprolidine drug combination | |
| dc.subject | Case report | |
| dc.subject | Human | |
| dc.subject | Multimodality cancer therapy | |
| dc.subject | Pathophysiology | |
| dc.title | Priapism, an emerging complication in β-thalassemia intermedia patients | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1